Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment

Hinpetch Daungsupawonga Private Academic Consultant, Phonhong, Lao People’s Democratic RepublicCorrespondence[email protected]

https://orcid.org/0009-0002-5881-2709 View further author information

Viroj Wiwanitkitb Department of Research Analytics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

https://orcid.org/0000-0003-1039-3728 View further author information

"Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment." Human Vaccines & Immunotherapeutics, 20(1), pp.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Authors’ contribution

HD 50% ideas, writing, analyzing, approval

vW 50% ideas, supervision, approval.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment

Information for

Open access

Opportunities

Help and information

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment

Disclosure statement

Authors’ contribution

Additional information

Funding

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature